Why Immutep's share price collapsed months after a major licensing win
Immutep signed a major regional licensing deal validating its lead cancer drug, only for its global Phase III lung cancer trial to fail a futility analysis months later.
31 Mar 2026 · 6 min read
In short
Immutep's share price fell around 85-88% in March 2026 after its Phase III TACTI-004 lung cancer trial was recommended for discontinuation following an interim futility analysis.
Just months earlier, the company signed a licensing deal with Dr Reddy's worth up to US$349 million in milestone payments plus royalties for regional rights to its lead drug.
Eftilagimod had a fifteen-year safety record across eleven trials and more than 650 patients prior to the trial halt, with safety concerns appearing to be a factor in the decision.
Cancer immunotherapy developer Immutep suffered one of the more dramatic single-day collapses among ASX biotechs in March 2026, falling around 85-88% after its Phase III TACTI-004 lung cancer trial for lead drug Eftilagimod was recommended for discontinuation following an interim futility analysis, an outcome Perennial Partners' March 2026 Monthly Report described as unexpected and disappointing given the product's performance in previous trials and the relatively low bar required to satisfy the futility analysis.
A licensing deal validated the drug just months before the trial failed
The collapse came only months after a major commercial validation of the same drug. Pengana Capital Group's December 2025 Monthly Report detailed a regional licensing deal with Indian pharmaceutical company Dr Reddy's covering all countries outside the US, Europe, Japan and Greater China, including US$20 million of upfront cash and US$349 million of potential milestone payments plus double-digit royalties, a transaction that highlighted the significant value of the remaining major-market rights relative to Immutep's market value of only US$450 million at the time. Pengana's report had also flagged a strategic relationship with Merck, producer of leading immunotherapy drug Keytruda, as raising the possibility of an eventual acquisition that could extend Merck's own franchise well beyond its 2028 patent expiry.
Immutep fell -88% after its global TACTI-004 Phase III trial was halted on risk/benefit grounds. Failure of this futility hurdle was a shocking outcome. Safety concerns appear to be a factor. Up till now their drug Efti had a fifteen-year safety record across eleven trials and over 650 patients.
— Quest Asset Partners, Quarterly Report, December 2025
Quest Asset Partners' reports detailed the specific shock of the failure: Eftilagimod had a fifteen-year safety record across eleven trials and more than 650 patients prior to the halt, with safety concerns appearing to be a factor in the decision to stop the lung cancer trial on risk-benefit grounds. Renaissance Asset Management's March 2026 Quarterly Report noted most of the company's value had been attributed to this prospective drug, and the manager ultimately sold the stock once the share price collapsed following the announcement.
What managers are watching next
Pengana Capital Group exited its position to realise the capital loss, stating it would revisit the company once there was more clarity on what went wrong in the trial, while Quest Asset Partners used the portfolio disruption to fund increases in other positions by reducing or exiting several holdings including Immutep entirely. With the company continuing to develop Eftilagimod in other cancer types and progressing an early-stage autoimmune program, IMP-761, that Pengana had earlier noted could attract high valuations even at an early stage, the central question for any remaining or future investors is whether the company's other pipeline assets can rebuild value following the lung cancer trial's failure.
Questions
Why did Immutep's share price collapse in March 2026?
Immutep's share price fell around 85-88% after its Phase III TACTI-004 lung cancer trial for lead drug Eftilagimod was recommended for discontinuation following an interim futility analysis, an unexpected outcome given the drug's prior trial performance.
What licensing deal had Immutep signed before the trial failure?
In December 2025, Immutep signed a regional licensing deal with Indian pharmaceutical company Dr Reddy's covering countries outside the US, Europe, Japan and Greater China, including US$20 million upfront and up to US$349 million in potential milestone payments plus royalties.
Does Immutep have other drug programs beyond the failed lung cancer trial?
Yes. Immutep continues to develop Eftilagimod in other cancer types and is progressing an early-stage autoimmune disease program, IMP-761, which Pengana Capital Group has noted could attract high valuations even at an early stage.
5 managers, 14 comments, with each manager's latest recorded position.
See IMM